PreveCeutical Medical Inc. (PREV.CN)
CAD 0.02
(0.0%)
CAD 0.02
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 963.12 Thousand CAD | -11.46% |
| 2022 | 1.08 Million CAD | 21.15% |
| 2021 | 897.85 Thousand CAD | -58.49% |
| 2020 | 2.16 Million CAD | -38.36% |
| 2019 | 3.5 Million CAD | -49.41% |
| 2018 | 6.93 Million CAD | 53.91% |
| 2017 | 4.5 Million CAD | 66.79% |
| 2016 | 2.7 Million CAD | 4227.59% |
| 2015 | 62.45 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 139.61 Thousand CAD | -60.14% |
| 2024 Q2 | 273.02 Thousand CAD | 97.37% |
| 2023 Q4 | 350.24 Thousand CAD | 128.74% |
| 2023 Q3 | 153.12 Thousand CAD | -4.35% |
| 2023 Q1 | 292.25 Thousand CAD | 12.06% |
| 2023 FY | 953.26 Thousand CAD | -12.36% |
| 2023 Q2 | 160.07 Thousand CAD | -45.23% |
| 2022 Q1 | 161.06 Thousand CAD | -44.34% |
| 2022 Q3 | 495.4 Thousand CAD | 185.06% |
| 2022 Q4 | 260.8 Thousand CAD | -47.35% |
| 2022 Q2 | 173.78 Thousand CAD | 7.9% |
| 2022 FY | 1.08 Million CAD | 21.15% |
| 2021 FY | 897.85 Thousand CAD | -58.49% |
| 2021 Q1 | 377.37 Thousand CAD | -75.48% |
| 2021 Q4 | 289.36 Thousand CAD | 431.83% |
| 2021 Q3 | -87.2 Thousand CAD | -127.4% |
| 2021 Q2 | 318.31 Thousand CAD | -15.65% |
| 2020 Q3 | -420.82 Thousand CAD | -156.19% |
| 2020 FY | 2.16 Million CAD | -38.36% |
| 2020 Q1 | 279.75 Thousand CAD | 55.35% |
| 2020 Q2 | 748.91 Thousand CAD | 167.7% |
| 2020 Q4 | 1.53 Million CAD | 465.72% |
| 2019 Q3 | 902.7 Thousand CAD | -34.01% |
| 2019 Q2 | 1.36 Million CAD | 29.17% |
| 2019 Q4 | 180.08 Thousand CAD | -80.05% |
| 2019 Q1 | 1.05 Million CAD | 2.21% |
| 2019 FY | 3.5 Million CAD | -49.41% |
| 2018 Q1 | 1.34 Million CAD | -42.75% |
| 2018 FY | 6.93 Million CAD | 53.91% |
| 2018 Q4 | 1.03 Million CAD | -58.5% |
| 2018 Q3 | 2.49 Million CAD | 19.12% |
| 2018 Q2 | 2.09 Million CAD | 56.29% |
| 2017 Q1 | 94.55 Thousand CAD | -20.86% |
| 2017 Q2 | 672.67 Thousand CAD | 611.4% |
| 2017 Q3 | 1.13 Million CAD | 68.33% |
| 2017 FY | 4.5 Million CAD | 66.79% |
| 2017 Q4 | 2.34 Million CAD | 106.89% |
| 2016 Q3 | 106.02 Thousand CAD | 297.5% |
| 2016 Q1 | 32.29 Thousand CAD | 90.42% |
| 2016 Q2 | 26.67 Thousand CAD | -17.41% |
| 2016 FY | 2.7 Million CAD | 4227.59% |
| 2016 Q4 | 119.47 Thousand CAD | 12.69% |
| 2015 Q4 | 16.96 Thousand CAD | 895.36% |
| 2015 FY | 62.45 Thousand CAD | 0.0% |
| 2015 Q3 | 1704.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 81.448% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 87.56% |
| BetterLife Pharma Inc. | 3.24 Million CAD | 70.276% |
| BioVaxys Technology Corp. | 2.4 Million CAD | 59.913% |
| ChitogenX Inc. | 2.83 Million CAD | 65.967% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 77.115% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 92.39% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | -70.671% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 81.063% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -3645.378% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | -42.745% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | 20.864% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -1236.058% |
| MYND Life Sciences Inc. | 1.47 Million CAD | 34.694% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | 19.893% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | 68.361% |
| Telescope Innovations Corp. | 6.35 Million CAD | 84.838% |